This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aytu BioScience, Inc.
Drug Names(s): tramadol hydrochloride, BVF-324
Description: Zertane (tramadol hydrochloride) exhibits activity at a variety of CNS and peripheral targets, including:
- Low affinity at the mu opioid receptor, at which it is an agonist
- Inhibition of norepinephrine and serotonin reuptake transporters
- Binding to alpha-2 adrenergic receptors, at which it is an agonist.
Ampio is also developing Zertane in combination with a PDE-5 inhibitor, found here.
Biovail and DMI BioSciences
In August 2007, Biovail announced that it has entered into a license and development agreement with an undisclosed, privately held, drug-development company for the exclusive global rights to BVF-324.
The agreement allows for the licensing of clinical data, intellectual property and the rights to develop, manufacture and market BVF-324 globally. In return, Biovail has paid an upfront fee, and is contingently obligated to make additional milestone payments, including upon the initiation of the first Phase III trial for the product and upon the first commercial sale of the product in the United States. The agreement also stipulates that Biovail make tiered, single-digit royalty payments on net commercial sales of the product.
In August 2010, based on a reassessment of the commercial opportunity for BVF-324 and taking into consideration the slower than expected enrollment rate in the Phase III trials, Biovail made the decision to terminate its...See full deal structure in Biomedtracker
Partners: Valeant Pharmaceuticals International, Inc. FBM Industria Farmaceutica Endo International plc
Additional information available to subscribers only: